Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial


Por: Wollenberg, A, Costanzo, A, Vestergaard, C, Masuda, K, Morawska, K, Vardar, B, Pandey, H, Sabatino, S and Carrascosa, JM

Publicada: 31 dic 2025 Ahead of Print: 27 nov 2025
Resumen:
ObjectiveTo report response maintenance in patients with moderate-to-severe Atopic Dermatitis (AD) upon continuous or downtitrated baricitinib treatment for 200 weeks.MethodsPatients with vIGA-AD (R) (validated Investigator Global Assessment for Atopic Dermatitis) score <= 2 at Week 52 treated with baricitinib 4 mg were re-randomized (1:1:1) to continue (4 mg), down-titrate (2 mg) or dose withdrawal (placebo). Response to continuous and downtitrated treatment was assessed from Week 52 to 200 in the overall substudy population (vIGA-AD 0,1,2) and in substudy patients with higher response (vIGA-AD 0,1) at Week 52.ResultsEfficacy was maintained in Week 52 responders (vIGA-AD 0,1,2) continuing baricitinib 4 mg, as measured by vIGA-AD (0,1) (Week 52 [51.2%], Week 200 [51.2%]); Eczema Area and Severity Index (EASI) 75 (Week 52 [82.1%], Week 200 [79.8%]). Patients with vIGA-AD (0,1) at Week 52 maintained higher response rates during continued treatment and after down-titration compared with overall substudy population.ConclusionAD symptom improvement was maintained up to Week 200 with baricitinib 4 mg. After down-titration, the vIGA-AD (0,1) response patient subgroup maintained clear or almost clear skin and itch response improvement. Clear or almost clear skin achievement may help identify optimal candidates for down-titration after 52 weeks of full-dose treatment.

Filiaciones:
Wollenberg, A:
 Univ Hosp Augsburg, Dept Dermatol & Allergy, Sauerbruchstr 6, D-86179 Augsburg, Germany

 Univ Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany

 Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergy, Munich, Germany

Costanzo, A:
 Univ Med Sch Dermatol, Via Alessandro Manzoni, Rozzano, Italy

Vestergaard, C:
 Aarhus Univ Hosp, Aarhus, Denmark

Masuda, K:
 Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto, Japan

Morawska, K:
 Eli Lilly & Co, Indianapolis, IN USA

Vardar, B:
 Eli Lilly & Co, Indianapolis, IN USA

Pandey, H:
 Eli Lilly & Co, Indianapolis, IN USA

Sabatino, S:
 Eli Lilly & Co, Indianapolis, IN USA

:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, IGTP, Badalona, Spain
ISSN: 09546634





Journal of Dermatological Treatment
Editorial
Taylor & Francis, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 36 Número: 1
Páginas: 2585244-2585244
WOS Id: 001626606400001
ID de PubMed: 41306112
imagen Green Submitted, gold

MÉTRICAS